Edition:
United States

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

14.51USD
18 May 2018
Change (% chg)

$0.06 (+0.42%)
Prev Close
$14.45
Open
$14.59
Day's High
$15.00
Day's Low
$14.40
Volume
22,568
Avg. Vol
37,272
52-wk High
$28.95
52-wk Low
$13.37

Chart for

About

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are... (more)

Overall

Beta: --
Market Cap(Mil.): $481.46
Shares Outstanding(Mil.): 20.53
Dividend: --
Yield (%): --

Financials

  SNNA.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.39 -- --
ROI: -- 1.57 14.38
ROE: -- 2.43 16.07

BRIEF-Sienna Biopharmaceuticals Reports Qtrly Loss Per Share $0.85

* SIENNA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 14 2018

BRIEF-Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma

* SEBACIA - ANNOUNCES FAVORABLE RULING BY U.S. FEDERAL COURT REGARDING PATENT INTERFERENCE PROCEEDINGS WITH SIENNA BIOPHARMACEUTICALS INC

May 07 2018

BRIEF-Sienna Biopharmaceuticals Appoints John Smither As CFO

* SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER

Mar 21 2018

BRIEF-Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56

* SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS

Mar 12 2018

BRIEF-Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125

Feb 14 2018

Earnings vs. Estimates